Investor Presentation Q1-Q3 2020

10 Investor presentation First nine months of 2020 International Operations had double digit diabetes sales growth across all regions and expanded Novo Nordisk market share Reported diabetes sales and growth per IO geography Diabetes value market share and share of growth in IO Novo NordiskⓇ 20 DKK billion 40 13% 33125 37% 30 ■Insulin I GLP-1 Growth at CER Market share -NN market share -NN share of growth 35% 30.0% 30% 25% Geographical area 20% 11% 1 10% 35% 15% 1 22.7% Market share +0.7-pp vs. 2019 12% 17% 10% 10 24% 51% 6% 5 5% 14% 12% 0 0% ΙΟ EMEA China ROW Aug 2018 Aug 2020 Source: IQVIA moving annual total, spot rate, Aug 2020 IO: International operations; NN: Novo Nordisk; pp: Percentage points; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; Row: Rest of World

View entire presentation